Sallmann and colleagues reported that adoptive transfer of the NKG2D specific CAR (CYAD-01) T cells in patients with AML or MDS showed promising response rates of 46% in a standalone phase I clinical trial enrolling relapsed/refractory AML patients (NCT03018405) [44]. The gene discussed is KLRK1; the disease is acute myeloid leukemia.